Find research datasets worth reusing
Search datasets from major research repositories and use ShareScore to quickly assess how well each record supports discovery, access, and reuse.
2,143
datasets available to search
ShareScore release 0.9.0
Dataset results
2,143 results for “All Spinal Cord”
Epidural Stimulation in Chronic Spinal Cord Injury Patients
ClinicalTrials.gov study NCT05690074. IPD Sharing: Not stated. Countries: 1. Publications: 7.
Cerebrospinal Fluid Drainage (CSFD) in Acute Spinal Cord Injury
ClinicalTrials.gov study NCT02495545. IPD Sharing: Not stated. Countries: 1. Publications: 36.
Effect of Sham Anti-inflammatory Diet on Inflammation After Spinal Cord Injury
ClinicalTrials.gov study NCT04271904. IPD Sharing: NO. Countries: 1. Publications: 3.
Data from: Mental health in individuals with spinal cord injury: the role of socioeconomic conditions and social relationships
Open the record for dataset details and reuse information.
Data from: Labor market integration of people with disabilities: results from the Swiss Spinal Cord Injury Cohort Study
Open the record for dataset details and reuse information.
Data from: Empirical targets for acute hemodynamic management of individuals with spinal cord injury
Open the record for dataset details and reuse information.
Data from: Down-regulation of CXCL12/CXCR4 expression alleviates ischemia-reperfusion-induced inflammatory pain via inhibiting glial TLR4 activation in the spinal cord
Toll-like receptor 4 (TLR4) is important for the pathogenesis of inflammatory reactions and the promotion of pain processing after ischemia/reperfusion (IR) in spinal cord. Recently, C-X-C chemokine ligand 12 (CXCL12) and its receptor, C-X-C chemokine receptor 4 (CXCR4), were demonstrated to be simultaneously critical for inflammatory reactions, thereby facilitating glial activation. However, whether CXCL12/CXCR4 expression can contribute to IR-induced inflammatory pain via spinal TLR4 remained unclear. A rat model was established by 8 min of aortic arch occlusion. The effects of CXCL12/CXCR4 expression and TLR4 activation on inflammatory hyperalgesia were investigated by pretreatments with CXCL12-neutralizing antibody, CXCR4 antagonist (AMD3100) and TLR4 antagonist (TAK-242) for 5 consecutive days before surgery. The results indicated that IR induced significant and sustained inflammatory pain, observed as decreases in paw withdrawal threshold (PWT) and paw withdrawal latency (PWL), throughout the post-injury period. The increased levels of TLR4 and proinflammatory chemokine CXCL12, as well as its receptor, CXCR4, were closely correlated with the PWT and PWL trends. Double immunostaining further suggested that TLR4, which is mainly expressed on astrocytes and microglia, was closely co-localized with CXCL12 and CXCR4 in spinal dorsal horn. As expected, intrathecal pretreatment with the TLR4 antagonist, TAK-242 markedly ameliorated pain by inhibiting astrocytic and microglial activation, as shown by decreases in TLR4 immunoreactivity and the percentage of double-labeled cells. These protective effects were likely due in part to the reduced production of the downstream cytokines IL-1β and TNF-α, as well as for the recruitment of CXCL12 and CXCR4. Additionally, intrathecal pretreatment with CXCL12-neutralizing antibody and AMD3100 resulted in similar analgesic and anti-inflammatory effects as those receiving TAK-242 pretreatment. These results suggest that intrathecal blockade of CXCL12/CXCR4 expression may attenuate IR-induced pain sensation and the release of inflammatory cytokines by limiting glial TLR4 activation in spinal cord.
Data from: High-dose methylprednisolone for acute traumatic spinal cord injury: A meta-analysis
Objective Due to the continuing debates on the utility of high-dose methylprednisolone (MP) early after acute spinal cord injury (ASCI), we aim to evaluate the therapeutic and adverse effects of high-dose MP according to NASCIS-2 dosing protocol in comparison to no steroids on patients with ASCI, by performing a meta-analysis on the basis of the current available clinical trials. Methods We searched PubMed and Cochrane Library (to May 22 2018) for studies comparing neurological recoveries, adverse events and in-hospital costs between ASCI patients who underwent high-dose MP treatment or not. Data were synthesized with corresponding statistical models according to the degree of heterogeneity. Results We enrolled 16 studies (1863 participants) including 3 RCTs and 13 observational studies. Pooled results indicated that MP was not associated with an increase in motor score improvement (RCTs: p = 0.84; Observational studies: p = 0.44) and incidence of recovery by at least one grade on the ASIA Impairment Scale (AIS) or Frankel (p=0.53). Meanwhile, MP did not lead to better sensory recovery (p=0.07). However, MP was associated with a significant higher incidence of gastrointestinal hemorrhage (p=0.04) and respiratory tract infection (p=0.01). The difference in the overall in-hospital costs between MP and control groups was not statistically significant (p=0.78). Conclusions Based on the current evidence, high-dose MP treatment, in comparison to controls, does not contribute to better neurological recoveries but may increase the risk of adverse events in patients with ASCI. Therefore, we recommend against routine use of high-dose MP early after ASCI.
Data from: Can microstructural MRI detect subclinical tissue injury in subjects with asymptomatic cervical spinal cord compression? a prospective cohort study
Objectives: Degenerative cervical myelopathy (DCM) involves extrinsic spinal cord compression causing tissue injury and neurological dysfunction. Asymptomatic spinal cord compression (ASCC) is more common but its significance is poorly defined. This study investigates if: 1) ASCC can be automatically diagnosed using spinal cord shape analysis; 2) multiparametric quantitative MRI can detect similar spinal cord tissue injury as previously observed in DCM. Design: Prospective observational longitudinal cohort study. Setting: Single centre, tertiary care and research institution. Participants: 40 neurologically intact subjects (19 female, 21 male) divided into groups with and without ASCC. Interventions: None. Outcome Measures: Clinical assessments: modified Japanese Orthopedic Association (mJOA) score and physical examination. 3T MRI assessments: automated morphometric analysis compared with consensus ratings of spinal cord compression, and measures of tissue injury: cross-sectional area (CSA), diffusion fractional anisotropy (FA), magnetization transfer ratio (MTR), and T2-weighted imaging white to grey matter signal intensity ratio (T2WI WM/GM) extracted from rostral (C1-3), caudal (C6-7), and maximally compressed levels (MCL). Results: ASCC was present in 20/40 subjects. Diagnosis with automated shape analysis showed area under the curve > 97%. Five MRI metrics showed differences suggestive of tissue injury in ASCC compared with uncompressed subjects (p<0.05), while a composite of all 10 measures (average of z scores) showed highly significant differences (p=0.002). At follow-up (median 21 months), two ASCC subjects developed DCM. Conclusions: ASCC appears to be common and can be accurately and objectively diagnosed with automated morphometric analysis. Quantitative MRI appears to detect subclinical tissue injury in ASCC prior to the onset of neurological symptoms and signs. These findings require further validation, but offer the intriguing possibility of pre-symptomatic diagnosis and treatment of DCM and other spinal pathologies. Registration: Not registered.
Natural hydrogels and spinal cord injury treatment
<p>Search Strategy </p>
Natural hydrogels and spinal cord injury treatment
<p>PRISMA 2020 Checklist</p>
Non-invasive recording of EEG from the cervical spinal cord via surface electrodes placed around the neck
<p>Data and scripts used for Chander et al. 2022. EEG data recorded via 10 electrodes placed around the neck of 17 healthy young human individuals, in addition to EEG data recorded from scalp electrodes (numbers of electrodes vary across individuals), an ECG channel, and EOG channels. The reference electrode was placed above the right acromion, the ground electrode above the left acromion. Sampling rate 5000 Hz, online lowpass filter 1000 Hz, online highpass filter .1 Hz (BrainAmp DC amplifier). During recordings, the left median nerve of participants was stimulated using a DS7 Digitimer at ~110% of motor threshold (constant current stimulation, 50-500 µsec pulse width (depending on the participant), square wave) at 3 Hz. 15% of stimuli were pseudo-randomly omitted. Participants counted the number of omissions in each of 3 minute blocks. The montage for neck electrodes is explained in Chander et al. 2022. There are three trigger values: 1 = experimenter pressed a key to start the experiment, or to initiate a new block. 130 = median nerve stimulation. 99 = omission. Further details in Chander et al. 2022. The scripts are mostly aiming at characterizing high-frequency signals (400-1200 Hz) in response to median nerve stimulation (8 to 16 ms), and their dissociation from the evoked response.</p>
Dataset related to article "SUNITINIB-MEDIATED INHIBITION OF STAT3 IN SKELETAL MUSCLE AND SPINAL CORD DOES NOT AFFECT THE DISEASE IN A MOUSE MODEL OF ALS"
<p>Dataset related to the article</p>
Distinction of self-produced touch and social touch at cortical and spinal cord levels
<p>Dataset for tatcile self-other-distinction study</p>
Metabolic and Stress Response Changes Precede Disease Onset in the Spinal Cord of Mutant SOD1 ALS Mice
<p>Many Amyotrophic Lateral Sclerosis (ALS) patients experience hypermetabolism, or an increase in measured versus calculated metabolic rate. The cause of hypermetabolism and the effects on neuronal metabolism in ALS are currently unknown, but the efficacy of dietary interventions shows promise for metabolism as an ALS therapeutic target. The goal of this study is to measure changes in metabolic pathways as a function of disease progression in spinal cords of the SOD1G93A mouse model of ALS. We conducted a comprehensive assessment of protein expression for metabolic pathways, antioxidants, chaperones, and proteases in lumbar spinal cord from male SOD1G93A mice at pre-onset, onset, and end-stages of the disease using targeted proteomic analysis. These results reveal that protein content of metabolic proteins including proteins involved in glycolysis, β‐oxidation, and mitochondrial metabolism is altered in SOD1G93A mouse spinal cord well before disease onset. The changes in mitochondrial metabolism proteins are associated with decreased maximal respiration and glycolytic flux in SOD1G93A dermal fibroblasts and increased hydrogen peroxide and lipid hydroperoxide production in mitochondria from sciatic nerve and gastrocnemius muscle fibers at end stage of disease. Consistent with redox dysregulation, expression of the glutathione antioxidant system is decreased, and peroxiredoxins and catalase expression are increased. In addition, stress response proteases and chaperones, including those involved in the mitochondrial unfolded protein response, are induced before disease onset. In summary, we report that metabolic and stress response changes occur in SOD1G93A lumbar spinal cord before motor symptom onset, and are primarily caused by SOD1G93A expression and do not vary greatly as a function of disease course.</p>
Trajectory Based Classification of Recovery In Sensorimotor Complete Traumatic Cervical Spinal Cord Injury – Individual Recovery Trajectory Data
<p><b>Objective</b></p> <p>To test the hypothesis that sensorimotor complete traumatic cervical spinal cord injury is a heterogenous clinical entity comprising several subpopulations that follow fundamentally different trajectories of neurological recovery.</p> <p><b>Methods</b></p> <p>We analyzed demographic and injury data from 655 patients who were pooled from four prospective longitudinal multicenter studies. Group based trajectory modeling was applied to model neurological recovery trajectories over the initial 12-months postinjury and to identify predictors of recovery trajectories. Neurological outcomes included: Upper Extremity Motor Score, Total Motor Scores and AIS grade improvement.</p> <p><b>Results </b></p> <p>The analysis identified three distinct trajectories of neurological recovery. These clinical courses included: (1) Marginal recovery trajectory: characterized by minimal or no improvement in motor strength or change in AIS grade status (remained grade A); (2) Moderate recovery trajectory: characterized by low baseline motor scores that improved approximately 13 points; or AIS conversion of one grade point; (3) Good recovery trajectory: characterized by baseline motor scores in the upper quartile that improved to near maximum values within three months of injury. Patients following the moderate or good recovery trajectories were of younger age, had more caudally located injuries, a higher degree of preserved motor and sensory function at baseline examination and exhibited a greater extent of motor and sensory function in the zone of partial preservation.</p> <p><b>Conclusion</b></p> <p>Cervical complete SCI can be classified into one of three distinct subpopulations with fundamentally different trajectories of neurological recovery. This study defines unique clinical phenotypes based on potential for recovery, rather than baseline severity of injury alone. This approach may prove beneficial in clinical prognostication and in the design and interpretation of clinical trials in SCI.</p>
Preventing Pressure Ulcers in Veterans With Spinal Cord Injury (SCI)
ClinicalTrials.gov study NCT00105859. IPD Sharing: Not stated. Countries: 1. Publications: 3.
Treatment of Spinal Cord Injury Using Autologous Concentrated Growth Factors
ClinicalTrials.gov study NCT07253233. IPD Sharing: NO. Countries: 0. Publications: 13.
Study to Determine if a Reduction in Pain Can be Measured in Spinal Cord Injured Patients Using a New Study Design
ClinicalTrials.gov study NCT00978341. IPD Sharing: Not stated. Countries: 1. Publications: 0.
Diaphragm Pacing in Individuals With Spinal Cord Injuries
ClinicalTrials.gov study NCT04179799. IPD Sharing: NO. Countries: 1. Publications: 0.
ScienceDex guides
Understand access before you commit
These curated guides explain access requirements, typical timelines, costs, and reuse considerations for widely used research datasets.
Allen Brain Atlas
Allen Brain Atlas is an Allen Institute collection of brain map atlases, datasets, APIs, and analysis tools covering mouse, human, and non-human primate brain resources.
Annotated Behaviour and Observability Dataset (ABODe)
ABODe is a University of Edinburgh DataShare dataset for behavior classification in group-housed mice using home-cage video, identities, bounding boxes, ground-plate positions, and annotator labels.
DANDI Archive for NWB datasets
DANDI is a BRAIN Initiative archive for publishing and sharing neurophysiology data, including electrophysiology, optophysiology, and behavioral data packaged as NWB and related standards.
International Brain Laboratory public data
The International Brain Laboratory public data releases expose standardized mouse decision-making experiments, including Neuropixels recordings, widefield calcium imaging, behavior, and session metadata accessed through the ONE API.
OpenNeuro
OpenNeuro is a free, open platform for sharing neuroimaging datasets, with public search, dataset pages, and download paths for web, S3, DataLad, and the OpenNeuro CLI.